Arizona News 12 NBC, February 22, 2022: Will this new law help women considering breast implants make informed medical decisions? The FDA took a step in the right direction but will doctors accurately inform their patients?
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
FDA’s agenda in limbo as Biden’s nominee stalls in Senate
Fox13, February 9, 2022: President Joe Biden’s pick to lead the Food and Drug Administration has stalled in the narrowly divided Senate, an unexpected setback that could delay decisions on electronic cigarettes and other high-profile health issues. Will all the publicity help Califf get confirmed, given the alternatives?
Read More »Biden’s ‘Cancer Moonshot’ Turns Toward Pollution
E&E News, February 3, 2022: President Biden made an emotional pledge to “end cancer as we know it” by reinvigorating the Cancer Moonshot Initiative he first launched in 2016, just one year after his son Beau succumbed to the disease. But experts, including us, point out that there isn’t enough focus on environmental causes of cancer.
Read More »What’s Wrong with the FDA?
Washington Monthly, January 20, 2022: If Robert Califf, the White House nominee for commissioner of the FDA, is confirmed by the Senate, he’ll take the reins of an agency with its reputation in tatters. Once revered as the global leader in drug regulation, the FDA has approved one bad drug and medical device after another over the past 30 years, leaving staff demoralized and overseas regulators scratching their heads. NCHR and other experts provide recommendations for improvements.
Read More »Biogen Alzheimer’s Drug Coverage Threatens Minorities’ Access
Bloomberg Law, January 13, 2022: Minority groups could have a harder time accessing Aduhelm, Biogen Inc.’s Alzheimer’s drug, under Medicare’s preliminary decision to limit coverage to patients enrolled in clinical trials, policy analysts say. But we explain that it will ensure that patients understand that the drug is experimental, with proven risks but no proven benefits.
Read More »